| Date | Title | Description |
| 16.07.2026 | AdvanCell Closes $315 Million Series D |
BOSTON, MA, AdvanCell, a clinical-stage radiopharmaceutical company, announced the closing of an oversubscribed and upsized $315 million Series D financing.
>> Click here for more funding data on AdvanCell
>> To export AdvanCel... |
| 05.05.2026 | Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent | Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, today announces the appointments of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, a... |
| 17.03.2026 | Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306 | AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis
Alebund grants exclusive rights to develop, manufacture, an... |
| 17.03.2026 | R1 Therapeutics: $77.5 Million Raised To Advance Kidney Disease Treatment | R1 Therapeutics, a clinical-stage biopharmaceutical company focused on kidney disease, has launched with an oversubscribed $77.5 million Series A financing to advance a first-in-class treatment for hyperphosphatemia in patients with chronic... |
| 17.03.2026 | R1 Therapeutics Raises $77.5M in Series A Funding | R1 Therapeutics, a Redwood City, CA-based clinical-stage biopharmaceutical company, raised $77.5M in Series A funding.
The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, with participation from Curie.Bio, SymBiosis, and ... |
| 27.12.2025 | Addition Therapeutics: $100 Million Funding Raised To Advance All-RNA PRINT Platform For One-Time Genomic Medicines | Addition Therapeutics announced it has raised $100 million in financing to date, highlighting progress toward developing one-time genomic medicines for chronic and rare diseases. Based in South San Francisco, the company is building around ... |
| 17.12.2025 | Addition Therapeutics Raises $100M in Funding | Addition Therapeutics, a San Francisco, CA-based genomic medicine company, raised $100M in funding.
Backers included SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation, and BEVC.
The company intends t... |
| 12.11.2025 | AI-Driven Biotech Iambic Secures Over $100M for Drug Discovery | Iambic, a San Diego AI-driven biotech, secured over $100M in funding. This capital fuels its advanced AI drug discovery platform and expanding clinical pipeline. The company rapidly advances novel therapies, like IAM1363, showing strong ant... |
| 11.11.2025 | Iambic Raises Over $100M in Funding | Iambic, a San Diego, CA-based clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, raised over $100M in funding.
Backers included Abingworth, Alexandria Ventur... |
| 10.11.2025 | Iambic: $100 Million Raised To Advance AI-Discovered Therapeutics And Platform Technologies | Iambic, a clinical-stage life science and technology company headquartered in San Diego, announced that it has raised more than $100 million in an oversubscribed financing round. The round drew participation from a broad group of new and ex... |
| 05.09.2025 | Wugen Secures $115M: Off-the-Shelf CAR-T Fuels Cancer Fight | Wugen, a St. Louis-based biotech, secured $115 million in new funding. Fidelity Management led the significant investment round. The capital propels WU-CART-007, Wugen's cutting-edge allogeneic CAR-T cell therapy. This innovative "off-... |
| 04.09.2025 | Wugen: $115 Million Raised To Advance CAR-T For T-Cell Cancers | Wugen, a clinical-stage biotechnology company based in St. Louis, has announced the closing of a $115 million equity financing round. The investment, led by Fidelity Management & Research Company and joined by a consortium of life scien... |
| 28.08.2025 | Wugen Raises $115M in Funding | Wugen, a St. Louis, MO-based clinical-stage biotechnology company, raised $115M in funding.
The round was led by Fidelity Management and Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, I... |
| 16.04.2025 | Glycomine Raises $115M in Series C Financing | Glycomine, a San Carlos, CA-based biotechnology company focused on developing new therapies for orphan diseases, raised $115M in Series C funding.
The round was led by CTI Life Sciences Fund, abrdn Inc., and Advent Life Sciences, with parti... |
| 14.04.2025 | Atsena Therapeutics: $150 Million (Series C) Closed To Advance Ocular Gene Therapy Programs | Atsena Therapeutics – a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness – recently announced the closing of an oversubscribed $150 million Series C fnuding.... |
| 04.04.2025 | Atsena Therapeutics Raises $150M in Series C Financing | Atsena Therapeutics, a Durham, NC-based clinical-stage gene therapy company, raised $150M in Series C funding.
The round was led by Bain Capital’s Life Sciences team, with participation from an additional new investor, Wellington Management... |
| 05.03.2025 | Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director | ROCKVILLE, Md., March 5, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene to GMP advanced therapy development partner, today announced the appointment of John Chiminski and Karen Flynn as non-executive members of its Board of... |
| 10.02.2025 | AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing | Sydney, Australia – 3 February 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This ... |
| 08.02.2025 | AdvanCell: Radiopharmaceutical Company Raises $112 Million (Series C) | AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed $112 million Series C financing. This milestone funding round was co-led by SV... |
| 16.01.2025 | Timberlyne Therapeutics: $180 Million (Series A) Raised For Advancing CM313 | Timberlyne Therapeutics – a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune disorders – announced the closing of a $180 million Series A financing to advance CM313, a potentially best-in... |
| 13.01.2025 | Timberlyne: $180 Million (Series A) Raised To Develop Novel Therapies For Autoimmune Disorders | Timberlyne Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune disorders, announced the closing of a $180 million Series A financing to advance CM313, a potentially best-in-c... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 08.07.2024 | Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development | London, UK, 8 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financi... |
| 31.10.2023 | Abingworth: Transatlantic Life Sciences Investment Firm Closes $356 Million | Abingworth – a leading international life sciences investment group, part of global investment firm Carlyle – recently announced the final closing of its new Clinical Co-Development Co-Investment Fund at $356 million. Abingworth Clinical Co... |
| 30.10.2023 | Abingworth closes $356M fund for late-stage biopharma programs | Investor Abingworth has closed a new $356 million fund specifically designed to co-develop late-stage clinical programs with biotechs and pharmas.
Abingworth—an international life sciences investment group that was acquired last year by the... |
| 30.10.2023 | Abingworth Closes Clinical Co-Development Co-Investment Fund, at $356M | Abingworth, a global life sciences investment firm, closed its new Clinical Co-Development Co-Investment Fund, at $356M.
CCD-CIF received support from Abingworth’s existing investor base and added new investors from the US and Europe.
Abing... |
| 30.10.2023 | Carlyle’s life science investor Abingworth scores over $350m for new clinical co-invest fundraise | |
| 30.10.2023 | Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF) | - |
| 23.10.2023 | Which VCs are investing in rare diseases? | Firms include Chiesi Ventures, Frazier Healthcare Partners, OrbiMed, and Atlas Venture
In the United States alone 25 million people suffer from rare disease, a number that jumps to 400 million people globally. While 1 in 10 people will suff... |
| 12.04.2022 | Carlyle's acquisition of Abingworth brings $2 billion to fuel life science investments | Small but mighty transatlantic investment firm Abingworth has caught the attention—and appetite—of the Carlyle Group, who took the opportunity to gain a stronger foothold in life sciences.
Carlyle’s acquisition of Abingworth, announced Mond... |
| 11.04.2022 | Private equity giant Carlyle to acquire biotech venture capital firm Abingworth | The Carlyle Group will acquire Abingworth, one of biotech’s oldest venture capital groups, it announced Monday. The financial terms of the deal, which will close later this year, were not disclosed.
Abingworth, which just raised about $1 bi... |
| 11.04.2022 | Paradigm, Andreessen Horowitz, and Union Square Ventures sued over alleged ‘rampant fraud’ on Uniswap exchange | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
The most successful crypto funds have taken a hands-on approach with the founders they work with.... |
| 16.09.2021 | Anjarium Biosciences Raises CHF 55.5 Million Series A Financing | |
| 02.08.2021 | CymaBay Therapeutics : Announces $100 Million Non-Dilutive Financing with Abingworth | Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC
CymaBay retains full worldwide commercial rights to seladelpar
NEWARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NAS... |
| 02.08.2021 | CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth | - |
| 10.05.2021 | Abingworth raises $582 million for new Clinical Co-Development Fund – ACCD 2 | - |
| 08.05.2021 | Abingworth raises $582M clinical co-development fund amid rising biotech interest
Remarque Systems: Content Hub | Abingworth has raised $582 million for its second clinical co-development fund. The fund, ACCD 2, equips Abingworth to make triple-digit million investments in late-stage clinical programs.
London-based Abingworth got into clinical co-devel... |
| 04.02.2021 | Abingworth closes latest life sciences fund on $465M | London-based life sciences investor Abingworth has closed its eighth transatlantic venture fund on $465 million, exceeding its $375 million target. The vehicle will be used for seed and early-stage deals, as well as investments in public eq... |
| 03.02.2021 | Abingworth raises $465M fund, steps up interest in CNS diseases | Abingworth has raised a $465 million life sciences fund, positioning it to build on earlier investments in biotechs including Alnylam and CRISPR Therapeutics. The transatlantic fund will follow a similar playbook to its seven predecessors, ... |
| 03.02.2021 | Abingworth raises $465m for new life sciences fund Abingworth Bioventures 8 | - |
| 03.02.2021 | Abingworth raises $465m for new life sciences venture fund | - |
| 09.12.2020 | Congratulations to the Reneo team on their $95 Million Series B Financing, Co-led by Novo Ventures and Abingworth | - |
| 09.12.2020 | Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth | SAN DIEGO, Dec. 9, 2020 /PRNewswire/ -- Reneo Pharmaceuticals, Inc. today announced it raised $95 million in a Series B financing co-led by Novo Ventures and Abingworth and supported by existing investors New Enterprise Associates, RiverVes... |
| 20.02.2020 | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | - |
| 19.02.2020 | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | – Proceeds to advance development of Tildacerfont in Congenital Adrenal Hyperplasia and other indications
– Existing Investors Novo Holdings and RiverVest Venture Partners support the deal with new Investors HealthCap, Rock Springs Capital... |
| 26.03.2019 | Abingworth Appoints Bali Muralidhar as Partner | Abingworth, a London, UK-based international investment group dedicated to life sciences, appointed Bali Muralidhar as a Partner based in the London office.
Muralidhar has 15 years professional experience in healthcare across a range of fun... |
| 09.07.2018 | Term Sheet — Monday, July 9 | UNDER FIRE
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
The letter reads:
“Leveraged buyouts—such as those facilitated by your companies—often result in mass job loss, closure of profi... |
| 09.07.2018 | Abingworth Closes Abingworth Bioventures VII, at $315M | Abingworth, an international investment group focused on life sciences, closed its latest fund, Abingworth Bioventures VII (ABV VII), at $315m.
ABV VII, which exceeded its target of $300m, is Abingworth’s 12th fund. Its investor base includ... |
| 09.07.2018 | Abingworth raises $315M to place transatlantic biotech bets | Abingworth has raised a $315 million (€267 million) life sciences venture fund. The British VC shop will use the cash to continue placing bets on early to late-stage biotechs at home and abroad.
Sponsored by Agilent Technologies
How would y... |
| 06.11.2017 | NousCom secures €42 Million in Series B Financing | |
| 06.11.2017 | 5AM Ventures Joins 42M Euros Series B for NousCom | NousCom, an oncology company developing neoantigen based cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B financing. The round involved a syndicate of leading transatlantic life sciences... |
| 06.11.2017 | Versant Ventures Joins 42M Euros Series B for NousCom | NousCom, an oncology company developing neoantigen based cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B financing. The round involved a syndicate of leading transatlantic life sciences... |
| 25.07.2017 | Abingworth Joins $42M Series B for VenatoRx Pharmaceuticals | MALVERN, Pa.--(BUSINESS WIRE)--VenatoRx Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation antibiotics, today announced that it has raised $42 million in a Series B financing led by Versant Ventures and joined by ... |
| 21.01.2016 | Abingworth Closes 11th Life Sciences Fund, at $105M | Abingworth, an international investment group dedicated to life sciences, closed its 11th life sciences fund, at $105m.
Abingworth Clinical Co-Development Fund (ACCF), was oversubscribed, exceeding its target of $100 million, and will co-in... |
| 30.04.2015 | CRISPR Therapeutics Raises Additional $64 Million | |
| 03.06.2014 | Senseonics raised $20 million to advance continuous glucose monitoring implant | Pivotal trials have begun in Amsterdam and are scheduled for this summer in Germany and the UK and take about one year. After it secures a greenlight for its IDE application, Senseonics expects to begin clinical trials in the U.S. next year... |
| 16.05.2014 | Proteon Therapeutics Raises $45M in Series D Equity Financing | Proteon Therapeutics Inc., a Waltham, Mass.-based biopharmaceutical company developing pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, raised $45m in Series D equity financing.
This inclu... |
| 17.04.2014 | Wilson Therapeutics Receives $40M in Series B Funding | Wilson Therapeutics, a Stockholm, Sweden-based biopharmaceutical company, received $40m in Series B funding.
The round was co-led by Abingworth LLP and MVM Life Science Partners, with participation from founding investor HealthCap. In conju... |
| 28.02.2014 | Abingworth Closes £225m Fourth Fund | Abingworth, an international investment group dedicated to life sciences and healthcare, held the final closing of its £225m (approximately $375m) fund.
Abingworth Bioventures VI (ABV VI), Abingworth’s 10th life sciences fund, exceeded its ... |
| 20.05.2013 | eFFECTOR Therapeutics Completes $45M Series A Financing | eFFECTOR Therapeutics, a San Diego, CA-based newly formed biopharmaceutical company, completed a $45m Series A financing.
Backers included U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage... |
| 20.02.2013 | Gynesonics Raises $21M Series D Funding | Gynesonics Inc., a Redwood City, California-based women’s healthcare company, raised a $21m Series D funding.
The round was led by HBM Partners, with participation new investor Correlation Ventures and existing investors Abingworth, Advance... |
| 28.01.2013 | Avillion Receives Funding from Abingworth and Clarus Ventures | Avillion LLP, a London, UK-based company that focuses on clinical co-development of therapeutics, received initial funding from Abingworth LLP and Clarus Ventures.
Led by Lewis Cameron, CEO, John Bradshaw, CFO, and Dr Allison Jeynes-Ellis, ... |
| 04.06.2012 | Student-Led Wolverine Venture Fund Invests in Sonitus Medical | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
The Wolverine Venture Fund, a $5.5 million fund led by students at the University of Michigan, announced last week that it joined Arboretum Ventures in a $25 million Series A ... |
| 29.03.2012 | Sientra Closes $65M Series C Financing | Sientra, a Santa Barbara, CA-based medical device company focused on the aesthetic and plastic surgery markets, has closed a $65m Series C financing.
The round was led by Abingworth, with participation by Clarus Ventures, OrbiMed Advisors a... |
| 28.12.2011 | Minnesota medical device company targeting scoliosis raises $2.5 million | KSpine Inc. is led by CEO Fred W. Kornahrens. Longhini,who also is co-founder of Voyageur Medical, an early stage investor in medical device companies said that KSpine has raised $16 million since its launch in early 2008, primarily from tw... |
| 18.05.2011 | MD On-Line Receives Minority Investment from Abingworth | MD On-Line, Inc., a Parsippany, NJ-based provider of electronic data interchange (EDI) solutions that facilitate the critical connection between providers, insurance companies, pharmacies, laboratories, pharmaceutical companies, and other s... |
| 05.05.2010 | Secure EDI Receives Significant Investment from Abingworth | Secure EDI, a North Carolina, US-based healthcare transactions integrator, creating electronic interfaces between medical and dental providers and payers, has recived a “significant” growth equity investment from Abingworth, the internation... |
| 05.12.2008 | Broncus inhales $38M to treat lung disease, eyes IPO | Broncus Technologies, developer of devices to treat emphysema and other lung ailments, may make a second run at going public after bringing in $38 million in seventh-round funding to break even, reports VentureWire. The Mountain View, Calif... |
| 01.10.2008 | Pathwork Diagnostics raises $20M for cancer diagnostic tests | Pathwork Diagnostics, a Sunnyvale, Calif.-based maker of cancer diagnostic tets, has raised $20 million in a second round of funding. The round was led by new investor Abingworth Management, with participation from existing backers Advent V... |
| 24.06.2008 | Broncus Technologies lines up venture debt financing for emphysema treatment | Broncus Technologies pulled its initial public offering plans last week and now intends to line up venture debt financing, VentureWire reported.
Mountain View, Calif.-based Broncus is developing a minimally invasive treatment for emphysema.... |
| 08.05.2007 | Cardiovascular biotech Portola Pharmaceuticals raises $70M, eyes IPO | Portola Pharmaceuticals, a South San Francisco, Calif., biotech aiming to develop treatments for blood clots and other heart-related problems, raised $70 million in a third round of financing dominated by late-stage and public-market invest... |
| 29.09.2004 | Amadeus leads $14.4 million Series B financing in Solexa | Amadeus leads $14.4 million Series B financing in Solexa
29-09-2004
Amadeus Capital Partners has led a Series B financing of $14.
4 million in Solexa Ltd., a company at the forefront of developing systems that will allow the rapid sequencin... |
| 01.04.2004 | Abingworth wins Private Equity Awards | Abingworth wins Private Equity Awards
01-04-2004
Abingworth Management, the life sciences venture capital group, has won two Financial News Awards for Excellence in Private Equity: Best European Venture Capital Firm of the Year and Best Ven... |
| 16.08.2002 | Abingworth appoints in-house legal advisor | Abingworth appoints in-house legal advisor
16-08-2002
Abingworth, the life sciences venture capital group, has announced the expansion of its management team with the appointment of Claire Wilkinson as General Counsel.
Miss Wilkinson qualif... |
| - | Minnesota medical device company targeting scoliosis raises $2.5 million | A Minnesota medical device company has raised $2.5 million in its second round of financing, according to a Form D filing with the Securities and Exchange Commission. KSpine’s spinal implant to treat scoliosis requires a less invasive surgi... |
| - | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | – Proceeds to advance development of Tildacerfont in Congenital Adrenal Hyperplasia and other indications
– Existing Investors Novo Holdings and RiverVest Venture Partners support the deal with new Investors HealthCap Partners, Rock Spring... |
| - | Senseonics raised $20 million to advance continuous glucose monitoring implant | There are just a handful of big medical device companies that dominate the continuous glucose monitoring space and Senseonics is looking to compete with them. It has raised $20 million across two tranches from current investors to advance a... |
